N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053 or 053), a drug candidate discovered by our group, is a highly selective BCR-ABL kinase inhibitor against chronic myeloid leukemia (CML) with high potency (GI50: ~14 nM against K562 cells) [3]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.